PatientsVille.com Logo

RASH and Lithium

PatientsVille

RASH Symptoms and Causes

A Rash is an area of irritated or swollen skin. Many Rashes are itchy, red, painful, and irritated. Some Rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get Rashes.

Contact dermatitis is a common type of Rash. It causes redness, itching, and sometimes small bumps. You get the Rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy.

Some Rashes develop right away. Others form over several days. Although most Rashes clear up fairly quickly, others are long-lasting and need long-term treatment.

Because Rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad Rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

Check out the latest treatments for RASH

RASH treatment research studies

Lithium clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lithium Side Effects

Therapeutic Agent Toxicity (237)
Confusional State (205)
Tremor (179)
Toxicity To Various Agents (167)
Renal Failure Acute (132)
Dehydration (107)
Diarrhoea (106)
Nausea (96)
Nephrogenic Diabetes Insipidus (93)
Blood Creatinine Increased (91)
Dysarthria (87)
Agitation (83)
Mania (80)
Mental Status Changes (78)
Hyperparathyroidism (77)
Asthenia (77)
Dizziness (77)
Fall (72)
Renal Failure Chronic (71)
Vomiting (68)
Insomnia (66)
Disorientation (66)
Fatigue (61)
Gait Disturbance (61)
Bradycardia (61)
Depression (60)
Haemodialysis (57)
Completed Suicide (56)
Suicide Attempt (56)
Anxiety (56)
Somnolence (53)
Depressed Level Of Consciousness (53)
Overdose (52)
Renal Failure (51)
Hypercalcaemia (51)
Delirium (51)
Hypernatraemia (50)
Neuroleptic Malignant Syndrome (49)
Renal Cyst (49)
Hypotension (47)
Nephropathy (46)
Hypothyroidism (45)
Lethargy (45)
Condition Aggravated (45)
Ataxia (44)
Renal Impairment (43)
Coma (41)
Abnormal Behaviour (40)
Dyspnoea (40)
Weight Increased (39)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<span style='color: #808080;'><b>Describe Your Rash erythematous from DTAP (DAPTACEL) 2010 Experience Here:</b> <strong>My son 4 month, had an itchy redrash around his eyes and checks. Fever and Drowsy

Abdominal distention with lithium and seroquel. 20-30 yr. use

Developed bruxism after starting abilify and lithium

Had a small rash from my stomack to under my arm and doctor gave me zinnat 500mg twice a day after food, the doctor said it was due to a piercing i had done on my nose 4 weeks ago., but only after taking the tablets for 2days the rash has travelled t

Hey all my boyfriend has come up with a rash that's looks like blisters that varry in size also look looks crusty scaley its very painful and he says it feels like he is burning , I've noticed today that my son has started to come out in a couple of

I developed an itchy rash on my right foot which forms little sores on intensive itching and drying up looks like white crusts,its being on for over 2 months and is begining to spread to my other foot and arms

I have a rash on my neck and face.i have had these for three days and they are so itchy its unbelivable.i am 13 what could this be?

I have been using percocet for a few years and have recently dveloped a rash on my face and neck, would like to know if this is normal and how to releive it

I have had a red rash on my leg. It didn't itch it wasn't bothersome at all.well after wks it went away. THEN the same type of rash appeared on my arm. I don't know what's wrong somebody plz HELP!!! Im getting scared

I have this rash all over my body that kinda looks like the chicken pocks, but it doesn't itch. Does anyone know anything about it.

48 years of age. I was diagnosed with urinary tract infection. Had one dose of monuril 3 gr. After 7 hours developed skin rash on the back, arms and neck, generally swelling of the face, specially below the eyes, Had oral antihistamine and went to

I been taking pradaxa for 14 days and have a severe rash, doctor to start warfarin again.

I finished my 3rd Euflessa injection 5 days ago. I now have a miserable, itchy rash covering the entire knee. The rash appeared on the 3rd day and has gotten worse each day. The pain is much better. Do you think this is related to the Euflexxa?

I have rash on my back, arms, legs for almost a year. No doctors-family, dermatologist, allergist-- could tell me the cause. I finally figured out that was benefiber. Now my body is so sensitive. I still have rash from time to time and can not f

&amp;gt;:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

I have a severe rash all over my body and an inflamation in my throat. I all started the first day I took Captopril 100 mg twice a day.

<b>Describe Your Gastrografin Experience Here:</b>Itching, rash and diarrhea. Started as soon as test was finished. I ended up in the ER. I have an allergy to contrast dye. After reading about Gastrografin I see it contains Iodine.

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

<span style='color: #808080;'><b>Describe Your Rash erythematous from DTAP (DAPTACEL) 2010 Experience Here:</b> <strong>My son 4 month, had an itchy redrash around his eyes and checks. Fever and Drowsy

<span style='color: #808080;'><b>Describe Your TDAP (ADACEL) Experience Here:I received my vaccine on 2-28-2011</b> today is 3-4-2011 and my arm is still very sore and I have developed a raised rash on the upper arm al

RASH Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Tetracycline as a Prophylaxis for RASH in Patients With NSCLC Receiving Treatment With BIBW 2992
Conditions: Skin RASH;   Lung Cancer
Intervention: Drug: Tetracycline
Outcome Measures: Incidence and severity of RASH;   Quality of life;   RASH and progression free-survival;   RASH and overall survival
2 Recruiting 1% Topical Pimecrolimus Cream for the Treatment of the RASH Associated With ERBITUX
Condition: RASH
Intervention: Drug: Pimecrolimus
Outcome Measures: Prevention of cetuximab RASH;   Quality of Life
3 Not yet recruiting Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper RASH Prophylaxis
Condition: Diaper RASH
Interventions: Other: Moussik Diaper RASH Mousse;   Other: Desitin Creamy Ointment
Outcome Measures: Six point erythema skin grade;   Visual analogue scale (VAS) from 0 to 10
4 Recruiting Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream Lotion, for EGFR'I Induced Acneiform RASH
Condition: Acneiform RASH
Interventions: Drug: Threolone ointment;   Drug: ointment Synthomycine;   Drug: Aqua cream lotion
Outcome Measures: Number of patients developing grade 2 / above RASH under preventative treatment with ointment threolone, compared to the other 2 treatment arms.;   Number of patients developing a RASH under preventative treatment with ointment threolone, compared to the other 2 treatment arms
5 Recruiting Skin RASH Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Drug: Doxycycline;   Drug: Hydrocortisone 1% cream;   Other: Sunscreen;   Other: Moisturizer;   Drug: Clindamycin;   Drug: Medrol-dose pack (Steroid)
Outcome Measures: Incidence of RASH;   Quality of Life (QOL);   Adherence to treatment regimen;   Progression Free Survival
6 Recruiting Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) RASH in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Conditions: Cetuximab-induced Papulopustular (Acneiform) RASH Who Have;   Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Topical Dapsone 5% Gel;   Other: Moisturizer;   Drug: oral antibiotics
Outcome Measure: difference in lesion counts
7 Not yet recruiting Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study
Conditions: HIV;   Dried Blood Spot Method
Intervention: Other: Number of DBS Spots
Outcome Measure: Viable sample for HIV Testing
8 Recruiting Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Conditions: Polymorphic Light Eruption;   Psoriasis;   Atopic Eczema
Intervention:
Outcome Measures: Treg level and function;   Blood and/or skin cytokine and chemokine levels, vitamin D status, and other immunoregulatory parameters (see above)
9 Recruiting Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Gemcitabine;   Drug: Erlotinib;   Drug: Oxaliplatin;   Drug: Folinic Acid;   Drug: Irinotecan;   Drug: 5-FU
Outcome Measures: 1-year Survial rate of "good-risk" patients;   Evalutation of overall response rate, disease control rate and progression free survival;   Evaluation of adverse events;   Translational Projects
10 Unknown  The Spot Sign for Predicting and Treating ICH Growth Study
Condition: Intracerebral Hemorrhage
Interventions: Drug: recombinant activated factor VII;   Drug: placebo
Outcome Measures: Life-threatening thromboembolic complications defined as development of (1) acute myocardial ischemia; (2) acute cerebral ischemia; and (3) acute pulmonary embolism;   The rate of hematoma growth among spot sign positive subjects at 24 hours, comparing subjects treated with rFVIIa to those treated with placebo. Hematoma growth will be defined as a > 33% or > 6 cc increase in volume.;   The sensitivity and specificity of the spot sign for predicting hematoma growth;   Incidence of other potentially study drug related thromboembolic complications such as deep venous thrombosis and elevations in troponin not associated with ECG changes;   Ninety-day outcomes among spot positive subjects, dichotomized as modified Rankin Scale score of 0-4 verses 5-6, comparing subjects treated with rFVIIa to those treated with placebo;   The positive and negative predictive values of the spot sign and the accuracy of the site investigators for correct identification of the spot sign as compared to a blinded study neuroradiologist.;   Rate of total hemorrhage volume growth (hematoma + IVH) among spot-positive subjects.
11 Unknown  Regenecare® Wound Gel in Treating RASH in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
Conditions: Dermatologic Complications;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Dietary Supplement: collagen/aloe vera/vitamin E/lidocaine topical hydrogel
Outcome Measures: Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching;   Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of RASH;   Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0
12 Recruiting Vitamin D Supplementation in Polymorphic Light Eruption
Condition: Polymorphic Light Eruption
Interventions: Drug: Oral Vitamin D 3;   Drug: Miglyol 812 N
Outcome Measures: PLE test score (from 0-12) of experimental photo provocation;   Cytokine levels in serum;   Chemotaxis of neutrophils;   Level of regulatory T cells;   Quantification of skin alterations, including cellular infiltration and cytokine profile;   Dermatological quality of life (DLQI);   HADS (hospital anxiety and depression scale);   Function of regulatory T cells
13 Not yet recruiting Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous RASH Treatment
Condition: Cutaneous Hypersensitivity
Interventions: Drug: Desloratadine + Prednisolone;   Drug: Dexchlorpheniramine + Betamethasone
Outcome Measures: Efficacy of treatment in acute cutaneous RASH based on symptoms score;   Safety will be evaluated by the adverse event occurrences
14 Unknown  Does Acne RASH During Adolescence Predict Skin Reaction to Cetuximab
Condition: Colorectal Cancer Metastatic
Intervention: Drug: Cetuximab
Outcome Measure:
15 Recruiting Study of Procoagulation Markers in Stroke Patients
Conditions: Stroke;   Hyperglycemia;   Procoagulation Markers
Intervention: Other: Glycemic Control
Outcome Measures: change in biomarker between patients with favorable versus unfavorable functional outcome;   Changes in biomarker levels between patients with versus without stroke recurrence at 90 days post stroke.
16 Unknown  An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: HIV Infections
Intervention: Drug: HEC placebo gel
Outcome Measures: Presence or absence of bare spots with and without Gd.;   Quantification and location of bare spots.
17 Not yet recruiting A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI
Condition: RASH Due to Epidermal Growth Factor Receptor Inhibitors
Interventions: Drug: RECONVAL CREAM;   Drug: PLACEBO
Outcome Measure: Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI
18 Unknown  Elmex Gel Efficacy in Preventing White Spot Lesions
Condition: Dental Caries
Intervention: Drug: elmex gel
Outcome Measures: time and frequency of visually detected WSL (white spot lesions);   mineral loss according to QLF readings;   Frequency and chronoloy of WSL
19 Recruiting Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
Conditions: Cancer;   Skin RASH
Intervention: Other: cream
Outcome Measures: grade 2 or more papulopustular eruption;   impact of papulopustular eruptions on HRQoL;   patient tolerability and satisfaction of study cream;   effectiveness of study cream on the adherence;   other dermatological side effects
20 Not yet recruiting Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy
Condition: HIV/AIDS
Intervention:
Outcome Measures: Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #1 (initial study visit).;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #2.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with HIV viral suppression at study visit #3.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #1 (initial study visit).;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #2.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with self-reported adherence at study visit #3.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #1 (initial study visit).;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #2.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with pharmacy refill adherence at study visit #3.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #1 (initial study visit).;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #2.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) associated with and elevation in serum creatinine at study visit #3.;   Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #1 (initial study visit).;   Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #2.;   Level of TFV-DP in DBS in participants with wild-type vs. single nucleotide polymorphisms in ABCC2 (-24C>T, 1249G>A), ABCC4 (1612C>T, 3463G>A, 3724G>A, 4131T>G), and other relevant genes for tenofovir at study visit #3.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) at study visit #1 associated with HIV viral suppression at study visits #2 and #3.;   Level of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) at study visit #2 associated with HIV viral suppression at study visit #3.